NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 04/21/2022 17:44
Last Report Issued 08/19/2016 13:02

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2533SP
Patient ID 2533SP
Chain 16001134
DOB Not Given
Sex Not Given
Workorder 16001134
Received 08/17/2016

Lab ID 16001134-001
Matrix Serum or Plasma
Patient Name 2533SP
Patient ID 2533SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
2533SP Loperamide and Metabolite, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Loperamide	None Detected	ng/mL	5.0	

Synonym(s): Imodium®

Loperamide is a synthetic opioid derivative that has structural similarities to meperidine and diphenoxylate. It is effective against diarrhea resulting from gastroenteritis, inflammatory bowel disease, or unknown causes. It is available in tablets and capsules of 2 mg and liquids containing 1 mg/5 mL; the common dosage for adults is 4 mg several times daily until the diarrhea is controlled.

Approximately 40% of the drug is absorbed into the bloodstream after oral administration but, unlike most opioids, loperamide does not penetrate the blood-brain barrier very well. The drug is metabolized to inactive products and is eliminated through both the urine and the feces. The mean elimination half-life is approximately 10 hours.

Peak plasma concentrations occur approximately 5 hours after capsule administration and after about 2.5 hours

Results for sample 16001134-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 16001134-001
Matrix Serum or Plasma
Patient Name 2533SP
Patient ID 2533SP

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
after tablet or liquid use and common plasma concentrations are usually under 10 ng/mL. Reported concentrations in fatalities were reported as low as 77 ng/mL blood, and other drugs may also have been present. Adverse effects of loperamide after therapeutic doses may include dizziness, drowsiness, dry mouth and constipation. The drug does not produce typical opioid-like CNS effects except after very high doses.				
Desmethylloperamide	None Detected	ng/mL	5.0	
Synonym(s): Loperamide Metabolite				
Desmethylloperamide is an inactive metabolite of loperamide. Plasma concentrations following therapeutic loperamide dosing are usually under 20 ng desmethylloperamide/mL. Postmortem blood concentration in one fatality was reported at 380 ng desmethylloperamide/mL.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.